In line with these findings, our study revealed a distinct difference in patient PFS and OS based on the presence of U2AF1 mutations, indicating a significant adverse prognostic impact of U2AF1 mutations, particularly in young-onset MDS. This evidence concerns the gene U2AF1 and myelodysplastic syndrome.